News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Market Trends To Watch in 2024: Q&A With Seth Farbman, Chairman and Co-Founder of VStock Transfer

December 8, 2023
By Mike Hollan
Feature
Article

Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.

Seth Farbman

Seth Farbman
Chairman and co-founder
VStock Transfer

When it comes to the financial side of the life sciences industry, 2023 was a difficult year. After the pandemic brought a lot of interest and money to the industry, many companies struggled to raise money this year. Seth Farbman, chairman and co-founder of VStock Transfer, spoke with Pharmaceutical Executive about the trends he saw this year and what he expects in the coming year.

Pharmaceutical Executive: What trends are you seeing with pharmaceutical and life science-based IPOs in the last year?

Seth Farbman: I always tell people that if I knew those answers, I’d be in investment banking instead of doing what I do. I run a stock transfer agency which means we deal with the shares back and forth between the company and the shareholders. We sit in a unique position because we work with about 800 companies and our sweet spot is dealing with IPOs. For us, a deal is a deal and not necessarily worried about focusing on biotech or pharma. As a whole, however, the IPOs have been down by more than a third. From a biotech and pharma standpoint, we do have a lot of clients that fall into those categories. We’re seeing that they’re struggling to get money because investors seem to want to see companies that are at a later stage of progression.

Maybe three years ago, companies that were just starting out had people that were eager to invest in them and buy into the dream. Now, because of the hesitancy, investors want to see companies that are further along in the process and companies are struggling to find the initial capital.

PE: Where have they been finding this capital?

Farbman: They’re knocking on doors. They’ve had to resort back to everything from angel investors, crowd funding, and different mechanisms to get tranches of capital instead of the IPO, which was being able to raise $50-100 million at a time. Now, they’re forced to remain private longer, which means they have to find tranches of capital at lower amounts. That’s a struggle, because companies want to know that they have enough funding to last throughout testing and clinical trials.

PE: What lies ahead for pharma in 2024?

Farbman: We are seeing some trends, and I don’t know if this is from bankers, investors, or if it’s just overall buzz, but there’s a leaning towards some of the weight loss companies. We are also seeing a strong interest in foreign issuers. We’ve always dealt with foreign IPOs and companies who are looking to list on the NASDAQ. In the last six-to-seven months, we’ve had an overwhelming interest from places such as Singapore, Malaysia, and Hong Kong to bring those companies over to the US.

PE: Is the market returning to a pre-pandemic state or a new state?

Farbman: I don’t think we’re ever going to see it like pre-pandemic, where it was very healthy for IPOs. Anyone that was remotely connected to that industry certainly benefited. We were looking at a spark of the IPO industry coming back when everyone was looking at the Instacart or the Johnson & Johnson deals, but I don’t think those deals provided the ignition that we were all looking for. If those deals took off, they could have set the pathway on fire. Instead, we’re back to moving slow and steady, depending on the company, the valuations, and the story that’s being told.

I see 2024’s first quarter starting strong, but I don’t see everything being overly strong again.

PE: What are the key considerations for investors and companies looking to go public in the current market?

Farbman: From speaking to CEOs day in and day out, I’ve learned that companies need to get better at story telling. I don’t care if they’re in biotech, pharma, or medtech, they have to find a way to clearly tell their story so that it resonates both with the institutional and retail sides. When you’re dealing with biotech and pharma, they must distinguish themselves and explain why somebody should want to be looking at or investing in them now. If it’s just a run-of-the-mill story, the average investor or fund is going to say “come back in six months” because there’s no fear of missing out.

A lot of CEOs who are in the market now and need capital must explain why time is of the essence.

Recent Videos
Related Content

Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain

Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain

Don Tracy, Associate Editor
May 8th 2025
Article

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following herniorrhaphy and bunionectomy surgeries compared to placebo.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Lunit

Lunit’s AI Technology to Power German Radiology Network

Mike Hollan
May 8th 2025
Article

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.


Altman Ozbilge Wiseman

Enhancing Supply Chain Resilience amid Complexity in Pharma and Medical Devices

Jason Altman;Kerim Ozbilge;Chad Wiseman
May 8th 2025
Article

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.

Related Content

Impact, Access, and Scale: The Potential of India’s Pharma Market

Impact, Access, and Scale: The Potential of India’s Pharma Market

Roshel Jayasundera;Joshua Siow;Bhavna Desai
May 8th 2025
Article

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain

Viatris’ Meloxicam Formulation Demonstrates Efficacy in Post-Surgical Acute Pain

Don Tracy, Associate Editor
May 8th 2025
Article

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following herniorrhaphy and bunionectomy surgeries compared to placebo.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Lunit

Lunit’s AI Technology to Power German Radiology Network

Mike Hollan
May 8th 2025
Article

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years.


Altman Ozbilge Wiseman

Enhancing Supply Chain Resilience amid Complexity in Pharma and Medical Devices

Jason Altman;Kerim Ozbilge;Chad Wiseman
May 8th 2025
Article

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.